Pancreatic cancer
Merusā Zeno Shows Higher Response Rates in NRG1+ Pancreatic and Lung Cancers (ESMO 2023)
Anika Sharma
ESMO 2023: 1618P Currently, Ipsen’s Onivyde is the standard of care, but it offers only a 7% chance of response ...
Exelixis Celebrates Early End to Cabometyx Trial for Neuroendocrine Tumors due to Remarkable Efficacy
Anika Sharma
Exelixis, a drug developer, recently halted a cancer trial involving Cabometyx, their tyrosine kinase inhibitor, due to an overwhelming display ...
Continue to Evaluate TTFields in Pancreatic Cancer in the PANOVA-3 Trial
SG Tylor
Source – Novocure The Phase III PANOVA-3 trial, which is assessing Tumor Treating Fields (TTFields) therapy in combination with nab-paclitaxel ...
IA Gemcitabine Provides Survival Benefit in Patients with Locally Advanced Pancreatic Cancer
SG Tylor
Source –Ā RenovoRx The interim results of the Phase III TIGeR-PaC study (NCT03257033) presented at the 2023 European Society of ...
Zenocutuzumab receives Breakthrough Designation from the FDA for NRG1+ Pancreatic Cancer
SG Tylor
Source – Merus On July 5, The FDA has granted breakthrough therapy designation to zenocutuzumab (MCLA-128) as a treatment for ...
